Vantrexa · NSCLC · United States · Thoracic medical oncologist · captured by James Whitfield on 10 Sept 2026 · reviewed by Dr. Priya Raman on 12 Sept 2026
Verbatim as captured; never edited
Dr. Abbott raised that roughly a third of her first-line metastatic NSCLC patients present with asymptomatic brain metastases and that the VOYAGE-1 exclusion of untreated CNS disease makes it hard to offer vantrelimab to them. She said colleagues at two other centers share the concern and that without subgroup or real-world data she would default to chemo-immunotherapy in these patients.
Human-approved by Dr. Priya Raman on 12 Sept 2026
Multiple US academic centres are reluctant to use vantrelimab in patients with asymptomatic brain metastases because VOYAGE-1 excluded untreated CNS disease. Absence of subgroup or real-world data drives default to chemo-immunotherapy.
helixor-private-llm-2026.08 · generated 10 Sept 2026, 15:42 UTC
AI summary
Oncologist reports ~33% of 1L mNSCLC patients have asymptomatic brain metastases; VOYAGE-1 exclusion of untreated CNS disease limits vantrelimab use. Concern shared across ≥3 centres. Requests subgroup/RWE data.
Source spans used by the model
Dr. Abbott raised that roughly a third of her first-line metastatic NSCLC patients present with asymptomatic brain metastases and that the VOYAGE-1 exclusion of untreated CNS disease makes it hard to offer vantrelimab to them. She said colleagues at two other centers share the concern and that without subgroup or real-world data she would default to chemo-immunotherapy in these patients.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Evidence gap |
| Function | Clinical Development | Clinical Development |
| Priority | High | Critical |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 3 | 10% | 6.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 4 | 5% | 4.0 |
| Total | Critical 86 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 12 Sept 2026, 09:10 UTC | Update | PRDr. Priya Raman | ai.suggestedPriority | High → Critical | Breadth: ≥ 3 centres; brain-metastasis gap is a plan evidence gap | UI |
| 10 Sept 2026, 15:42 UTC | Update | JWJames Whitfield | ai.summary | — → AI summary generated (helixor-private-llm-2026.08, confidence 0.86) | — | AI |
| 10 Sept 2026, 15:42 UTC | Create | JWJames Whitfield | — | — → Captured from ENG-0007 | — | UI |
Every model call on this record and its human outcome
| Time | Feature | Model | User | Confidence | Outcome |
|---|---|---|---|---|---|
| 12 Sept 2026, 09:10 UTC | Insight summary | helixor-private-llm-2026.08 | Dr. Priya Raman | 86% | Corrected |
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
10 Sept 2026 · Dr. Andrea Abbott, Memorial Sloan Kettering · MSL James Whitfield
Insight
Reviewed 12 Sept 2026 by Dr. Priya Raman
Action
Initiative
Decision
Outcome
Closure